Collagen Solutions PLC Appointment of Chief Financial Officer (2585Z)

TIDMCOS

RNS Number : 2585Z

Collagen Solutions PLC

14 December 2017

Collagen Solutions Plc

(the "Company" or the "Group")

Appointment of Chief Financial Officer

Collagen Solutions plc (AIM: COS), a global supplier, developer and manufacturer of medical grade collagen and tissue components for use in regenerative medicine applications including orthopaedics, dental, wounds, and cardiovascular, is pleased to confirm the appointment of Hilary Spence as Chief Financial Officer ("CFO") as from 3 January 2018, based in our Glasgow office. Hilary will also join the Board at that time. Hilary takes over from Gill Black who has decided to step down as CFO and from the Board for family reasons. Gill will remain with the Company, maintain her role as Company Secretary and will assist Hilary in the smooth transition of roles.

Hilary has over 30 years' commercial experience in finance across a number of multi-sector businesses. Over her career Hilary has been involved in a number of successful business transformations where her diverse skills have been used to create, financially evaluate and implement growth strategies. Hilary has worked with a broad range of companies from large corporates including Heineken, Vodafone, Motorola and Premier Foods and smaller more entrepreneurial businesses. Most recently Hilary was Interim CFO at the private equity funded Powerleague, where she was integral to the restructuring and transformation of the finance systems.

Hilary is a Chartered Accountant, member of ICAS and has a BA in Business Economics and MBA from Strathclyde University.

Commenting on the appointment, Jamal Rushdy, CEO of Collagen Solutions said: "Hilary has a wealth of experience both commercially and financially, working with businesses that mirror Collagen Solutions growth model and we believe she will be an important asset to the business in this exciting period of transitional growth for the Company.

"I would also like to take this opportunity to thank Gill Black for her hard work over the last three and a half years as CFO. We are fortunate that she will be staying on within the finance team in Glasgow and assisting Hilary, particularly in the first few months of Hilary's induction within the business."

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014.

The following information is disclosed pursuant to Rule 17 and Schedule Two paragraph (g) of the AIM Rules for Companies in relation to Hilary Spence.

 
 Current Directorships        Previous Directorships 
---------------------------  ---------------------------------- 
 Giraff Limited               Craigholme School (Non Exec Board 
  School Leaver Network Ltd    member) 
                               Flying Pig Interim Management 
                               Limited 
---------------------------  ---------------------------------- 
 

Hilary Spence holds no ordinary shares in the capital of the Company.

Save as disclosed above there are no additional disclosures to be made in accordance with Rule 17 or Schedule Two paragraph (g) of the AIM Rules for Companies.

Enquiries:

 
 Collagen Solutions Plc                                                                     Via Lisa Baderoon 
 Jamal Rushdy, Chief Executive Officer 
  Head of Investor Relations                                                               Mob: [phone] 
   Lisa Baderoon ([e-mail]) 
 
 Cenkos Securities plc (Nominated                                                          Tel: [phone] 
  Adviser and Broker) 
  Stephen Keys 
  Steve Cox 
 
 Walbrook PR                                                    Tel: [phone] or [e-mail] 
 Mike Wort                                                                                 Mob: [phone] 
 Anna Dunphy                                                                               Mob: [phone] 
 
 

About Collagen Solutions:

Collagen Solutions Plc is a global provider of medical grade collagen formulations and components for use in regenerative medicine, medical devices and in-vitro diagnostics and research. The capabilities of the Company include the provision of native, soluble and powdered collagen formulations, processed and semi-processed tissues such as pericardium, bone, and blood vessels, and expertise in the development and contract manufacture of collagen components for use as engineered tissue scaffolds and other medical devices. These products are used in a wide variety of applications including orthopaedics, cardiovascular, dental, plastic surgery, wound healing, neurology and urology. Collagen Solutions' unique offering extends beyond material supply and contract services through the highly skilled staff who support customers through the various stages of development and regulatory approval. For additional information, please visit www.collagensolutions.com.

This information is provided by RNS

The company news service from the London Stock Exchange

END

BOALLFSVFFLVLID

(END) Dow Jones Newswires

December 14, 2017 02:01 ET (07:01 GMT)